230 related articles for article (PubMed ID: 15739120)
1. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
Charbonnel B; Roden M; Urquhart R; Mariz S; Johns D; Mihm M; Widel M; Tan M
Diabetologia; 2005 Mar; 48(3):553-60. PubMed ID: 15739120
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
[TBL] [Abstract][Full Text] [Related]
3. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.
Rodríguez A; Reviriego J; Karamanos V; del Cañizo FJ; Vlachogiannis N; Drossinos V;
Cardiovasc Diabetol; 2011 Feb; 10():18. PubMed ID: 21314919
[TBL] [Abstract][Full Text] [Related]
4. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
Raskin P; Matfin G; Schwartz SL; Chaykin L; Chu PL; Braceras R; Wynne A
Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
[TBL] [Abstract][Full Text] [Related]
5. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
Rajagopalan R; Xu Y; Abbadessa M;
Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
[TBL] [Abstract][Full Text] [Related]
6. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.
Perriello G; Pampanelli S; Di Pietro C; Brunetti P;
Diabet Med; 2006 Mar; 23(3):246-52. PubMed ID: 16492206
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
[TBL] [Abstract][Full Text] [Related]
8. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
[TBL] [Abstract][Full Text] [Related]
9. Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.
Roden M; Mariz S; Brazzale AR; Pacini G
J Intern Med; 2009 Apr; 265(4):476-87. PubMed ID: 19298459
[TBL] [Abstract][Full Text] [Related]
10. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Phielix E; Brehm A; Bernroider E; Krssak M; Anderwald CH; Krebs M; Schmid AI; Nowotny P; Roden M
Diabetes Obes Metab; 2013 Oct; 15(10):915-22. PubMed ID: 23574533
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ; Vergès B
Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.
Tripathy D; Daniele G; Fiorentino TV; Perez-Cadena Z; Chavez-Velasquez A; Kamath S; Fanti P; Jenkinson C; Andreozzi F; Federici M; Gastaldelli A; Defronzo RA; Folli F
Diabetologia; 2013 Oct; 56(10):2153-63. PubMed ID: 23811853
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes.
Tan MH; Glazer NB; Johns D; Widel M; Gilmore KJ
Curr Med Res Opin; 2004 May; 20(5):723-8. PubMed ID: 15140339
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
Pareek A; Chandurkar N; Thomas N; Viswanathan V; Deshpande A; Gupta OP; Shah A; Kakrani A; Bhandari S; Thulasidharan NK; Saboo B; Devaramani S; Vijaykumar NB; Sharma S; Agrawal N; Mahesh M; Kothari K
Curr Med Res Opin; 2014 Jul; 30(7):1257-66. PubMed ID: 24669876
[TBL] [Abstract][Full Text] [Related]
16. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
Garber AJ; Schweizer A; Baron MA; Rochotte E; Dejager S
Diabetes Obes Metab; 2007 Mar; 9(2):166-74. PubMed ID: 17300592
[TBL] [Abstract][Full Text] [Related]
17. [Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].
Rodríguez A; Reviriego J; Polavieja P; Mesa J
Med Clin (Barc); 2008 Nov; 131(19):721-30. PubMed ID: 19091199
[TBL] [Abstract][Full Text] [Related]
18. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
Ristic S; Collober-Maugeais C; Pecher E; Cressier F
Diabet Med; 2006 Jul; 23(7):757-62. PubMed ID: 16842480
[TBL] [Abstract][Full Text] [Related]
19. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
Bosi E; Ellis GC; Wilson CA; Fleck PR
Diabetes Obes Metab; 2011 Dec; 13(12):1088-96. PubMed ID: 21733058
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome.
Gupta AK; Smith SR; Greenway FL; Bray GA
Diabetes Obes Metab; 2009 Apr; 11(4):330-7. PubMed ID: 19267711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
